Skip to main content

Table 3 Distribution of RASSF1A promoter methylation by clinicopathological classifications and protein expression in ESCC and GCA tissues

From: Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China

Classification

ESCC (n=143)

GCA (n=92)

N

Methylated

Unmethylated

P

OR

(95%CI)

N

Methylated

Unmethylated

P

OR

(95%CI)

n

(%)

n

(%)

n

(%)

   

n

(%)

n

(%)

n

(%)

   

Gender

                  

Male

82

(57)

43

(52)

39

(48)

   

58

(63)

37

(64)

21

(36)

   

Female

61

(43)

33

(54)

28

(46)

0.84

0.94

(0.48–1.82)

34

(37

23

(68)

11

(32)

0.71

0.84

(0.34–2.07)

Age (y)

                  

≤50

25

(17)

13

(52)

12

(48)

   

21

(23)

16

(76)

5

(24)

   

50–60

48

(34)

37

(77)

11

(23)

0.03

3.11

(1.10–8.73)

32

(35)

19

(59)

13

(41)

0.21

0.46

(0.13–1.56)

>60

70

(49)

26

(37)

44

(63)

0.20

0.55

(0.22–1.37)

39

(42)

25

(64)

14

(36)

0.34

0.56

(0.17–1.85)

Gross pathologic classification Φ

               

1

38

(27)

18

(47)

20

(53)

   

17

(18)

10

(59)

7

(41)

   

2

25

(17)

16

(64)

9

(36)

0.58

0.74

(0.25–2.20)

32

(34)

24

(67)

8

(33)

0.25

2.10

(0.60–7.36)

3

29

(20)

19

(66)

10

(34)

0.91

0.92

(0.23–3.77)

33

(36)

21

(64)

12

(36)

0.74

1.23

(0.37–4.06)

4

19

(13)

15

(79)

4

(31)

0.06

0.39

(0.14–1.05)

ND

ND

ND

ND

ND

ND

   

Unclear

32

(22)

8

(25)

24

(75)

   

10

(11)

5

(50)

5

(50)

   

Differentiation classification

               

High

32

(22)

22

(69)

10

(31)

   

20

(22)

14

(70)

6

(30)

   

Middle

70

(49)

27

(39)

43

(61)

0.006

0.28

(0.12–0.69)

31

(34)

22

(71)

9

(29)

0.94

1.05

(0.31–3.59)

Low

34

(24)

26

(76)

8

(24)

0.48

1.48

(0.50–4.39)

41

(45)

24

(59)

17

(41)

0.39

0.61

(0.19–1.89)

Unclear

7

(5)

1

(14)

6

(86)

   

ND

ND

ND

ND

ND

ND

   

Tumor stage (T) classification

                

T1+T2

25

(17)

13

(52)

12

(48)

   

14

(15)

9

(64)

5

(36)

   

T3+T4

113

(79)

62

(55)

51

(45)

0.38

1.38

(0.68–2.82)

78

(85)

51

(65)

27

(35)

0.77

1.20

(0.36–4.04)

Unclear

5

(3)

2

(40)

3

(60)

   

ND▲

ND

ND

ND

ND

ND

   

Tumor stage (N) classification

                

N0

91

(64)

48

(53)

43

(47)

   

44

(48)

28

(64)

16

(36)

   

N1

47

(33)

27

(57)

20

(43)

0.60

1.21

(0.60–2.46)

48

(52)

32

(67)

16

(33)

0.76

1.143

(0.48–2.70)

Unclear

5

(3)

1

(20)

4

(80)

   

ND

ND

ND

ND

ND

ND

   

Tumor stage (TNM) classification

                

I+II

91

(64)

47

(52)

44

(48)

   

47

(51)

30

(64)

17

(36)

   

III+IV

47

(33)

28

(60)

19

(40)

0.38

1.38

(0.68–2.82)

45

(49)

30

(67)

15

(33)

0.78

1.13

(0.48–2.68)

Unclear

5

(3)

1

(20)

4

(80)

   

ND

ND

ND

ND

ND

ND

   

RASSF1A protein

                  

positive

17

(63)

6

(35)

11

(65)

   

14

(58)

5

(36)

9

(14)

   

negative

10

(37)

7

(70)

3

(30)

0.09

0.23

(0.04–1.25)

10

(42)

10

(100)

0

(0)

0.001

  
  1. Φ: Histopathologically, the gross pathologic types were different for ESCC and GCA, in ESCC, 1: medullary; 2: fungating; 3: ulcerating; 4: constriction & intraluminal; in GCA, 1: protruding; 2: ulcerating; 3: infiltrating.
  2. ▲: Not detected.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us